Elliott Management closed a governance agreement with Dexcom that places two directors on the continuous glucose monitor manufacturer's board. The arrangement ends Elliott's campaign without a proxy fight. Dexcom carries a $23 billion market capitalization and trades at 42x forward earnings as of Thursday's close.
CEO Jake Leach used the settlement announcement to detail product timelines at an investor day. The G8 sensor enters full commercial launch in Q2 2025 after limited release began in January. Dual-analyte sensing technology—tracking glucose and ketones simultaneously—remains in clinical trials with a 2027 target for FDA submission. Medicare Advantage coverage now reaches 18 million eligible patients, up from 12 million in 2023, following CMS reimbursement changes that took effect January 1.
The Elliott appointment matters because continuous glucose monitoring sits inside a margin compression cycle. Dexcom's gross margin fell 320 basis points year-over-year in Q4 2024 to 61.2% as the company shifted toward over-the-counter distribution and pharmacy channels. Revenue growth decelerated to 11% in 2024 from 24% in 2023. Abbott's FreeStyle Libre commands 58% of the global CGM market versus Dexcom's 31%, and Abbott's sensor requires no fingerstick calibration while Dexcom's G7 still recommends occasional blood glucose checks. The board additions signal Elliott believes Dexcom's operational tempo—not its technology—needs recalibration.
The G8 device represents Dexcom's answer. The sensor reduces size by 30% versus G7 and extends wear time to 15 days from ten. More relevant to allocators: G8 manufacturing occurs entirely in Dexcom's Mesa, Arizona facility, eliminating the split production with contract manufacturers that caused supply constraints in 2023. The company guided 2025 revenue growth to a range of 11% to 13%, implying $4.8 billion at the midpoint. Operating margin expansion of 200 basis points depends on G8 attachment rates exceeding 40% of new patient starts by year-end.
Operators should track three events. First, watch G8 uptake data when Dexcom reports Q1 earnings in late April—the company must show existing G7 users converting without churn. Second, monitor Abbott's Q1 call in mid-April for FreeStyle Libre 3 growth in the U.S. pharmacy channel, where Dexcom lost 280 basis points of share in 2024. Third, CMS releases 2026 Medicare Advantage reimbursement proposals in early June; any reduction in durable medical equipment rates directly impacts Dexcom's $1.1 billion Medicare book.
Elliott typically holds healthcare positions for 18 to 24 months. The fund took a stake in Dexcom during Q3 2024 when shares traded near $68. Thursday's close at $79.40 puts Elliott up roughly 17% before the governance agreement. The board seats cost nothing. The margin expansion timeline starts now.